Feline calicivirus vaccine

Alphavirus RNA replicon particles encoding FCV capsid proteins address the ineffectiveness of current vaccines by inducing broad protective immunity against diverse FCV strains, reducing disease severity and transmission in cats.

JP7721604B2Active Publication Date: 2025-08-12INTERVET INT BV
3 Cites 0 Cited by

Patent Information

Application Number
JP2023135198
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-12-08
Filing Date
2023-08-23
Publication Date
2025-08-12
Estimated Expiration
2038-11-05

AI Technical Summary

Technical Problem

Current vaccines for feline calicivirus (FCV) are ineffective against antigenically diverse strains, leading to uncontrolled outbreaks and high mortality, as they fail to induce broad protective immunity against new FCV isolates.

Method used

Development of immunogenic compositions using alphavirus RNA replicon particles that encode FCV capsid proteins, including virulent systemic FCV (VS-FCV) antigens, to enhance protective immunity against FCV and other feline pathogens.

Benefits of technology

The vaccine induces robust protective immunity against FCV strains, reducing disease severity and transmission, and can be administered without adjuvants, providing effective protection against FCV and related feline diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007721604000001
    Figure 0007721604000001
  • Figure 0007721604000002
    Figure 0007721604000002
  • Figure 0007721604000003
    Figure 0007721604000003
Patent Text Reader

Abstract

To provide a novel feline calicivirus vaccine including a polyvalent vaccine.SOLUTION: The present invention relates to a vaccine for assisting in prevention of a disease caused by feline calicivirus (FCV), comprising a Venezuelan Equine Encephalitis (VEE) alphavirus RNA replicon particle that encodes one or more FCV antigens and a pharmaceutically acceptable carrier. Here, the FCV antigen is a capsid protein selected from the group consisting of FCV F9-Like capsid protein and virulent systemic FCV (VS-FCV) capsid protein.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • tc-83-derived alphavirus vectors, particles and methods

    JP2007537761A

  • Hemorrhagic feline calicivirus

    US7449323B2

  • Feline calicivirus vaccine

    WO2017109045A1